FMP
VolitionRx Limited
VNRX
AMEX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
0.484 USD
-0.01 (-2.07%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
13.43k
90.03k
306.39k
775.3k
1.23M
2.34M
4.44M
8.43M
16M
30.36M
Revenue %
-
570.25
240.3
153.04
59.1
89.78
89.78
89.78
89.78
Operating Cash Flow
-16.46M
-20.85M
-15.28M
-18.06M
-25.89M
-2.34M
-4.44M
-8.43M
-16M
-30.36M
Operating Cash Flow %
-122.57k
-23.16k
-4.99k
-2.33k
-2.1k
-100
-100
-100
-100
Cap Ex
-1.94M
-973.56k
-1.57M
-1.08M
-277.5k
-1.98M
-3.75M
-7.12M
-13.52M
-25.66M
Cap Ex %
-14.45k
-1.08k
-512.47
-139.78
-22.5
-84.5
-84.5
-84.5
-84.5
Free Cash Flow
-18.41M
-21.83M
-16.85M
-19.15M
-26.17M
-4.32M
-8.2M
-15.55M
-29.52M
-56.02M
Weighted Average Cost Of Capital
Price
0.48
Beta
Diluted Shares Outstanding
86.53M
Costof Debt
18.22
Tax Rate
After Tax Cost Of Debt
18.22
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
1.87M
Total Equity
41.88M
Total Capital
43.75M
Debt Weighting
4.27
Equity Weighting
95.73
Wacc
9.6
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
13.43k
90.03k
306.39k
775.3k
1.23M
2.34M
4.44M
8.43M
16M
30.36M
Operating Cash Flow
-16.46M
-20.85M
-15.28M
-18.06M
-25.89M
-2.34M
-4.44M
-8.43M
-16M
-30.36M
Cap Ex
-1.94M
-973.56k
-1.57M
-1.08M
-277.5k
-1.98M
-3.75M
-7.12M
-13.52M
-25.66M
Free Cash Flow
-18.41M
-21.83M
-16.85M
-19.15M
-26.17M
-4.32M
-8.2M
-15.55M
-29.52M
-56.02M
Wacc
9.6
9.6
9.6
9.6
9.6
Pv Lfcf
-3.94M
-6.82M
-11.81M
-20.45M
-35.42M
Sum Pv Lfcf
-78.45M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.6
Free Cash Flow T1
-57.14M
Terminal Value
-751.49M
Present Terminal Value
-475.12M
Intrinsic Value
Enterprise Value
-553.57M
Net Debt
-1.4M
Equity Value
-552.17M
Diluted Shares Outstanding
86.53M
Equity Value Per Share
-6.38
Projected DCF
-6.38 1.076%
